A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
← catalyst calendarNCT06609226 · readout in 1,593 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
480estimated
Sites
106
Countries
Canada, Egypt, France +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-10 | actual | When the study began enrolling |
| Primary completion | 2030-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sickle Cell Disease
- Thalassemia
Interventions
- Drug: Etavopivat A
- Drug: Etavopivat B
- Drug: Etavopivat C
Primary outcomes
what the primary-completion date above is the date OFNumber of treatment emergent adverse events (TEAEs), reported for each indication and age group separately
measured Baseline (week 0 of FLORAL) up to end of study (up to week 316)
Number of adverse reactions, reported for each indication and age group separately
measured Baseline (week 0 of FLORAL) up to end of study (up to week 316)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed